EGFR and anemia (phenotype): In addition, PS 0/1/2 (P=0.0002), stage IIIB disease (P=0.0011), a history of EGFR-TKI treatment (P=0.0007), female gender (P=0.0320), grade 3 or 4 neutropenia (P=0.0002) and grade 0 anemia (P<0.0001) were also independent favorable prognostic factors (Table IV).